Eli Lilly and Company announced significant strategic collaborations to expand its pipeline into genetic medicines. The company partnered with MeiraGTx to develop and commercialize gene therapies for eye diseases, including a late-stage asset for a rare inherited retinal disease that has shown promising clinical results in restoring vision to children. This deal involves a $75 million upfront payment to MeiraGTx, with potential for over $400 million in future milestone payments. In a separate agreement, Lilly is collaborating with SanegeneBio to pursue RNA interference (RNAi) therapies for metabolic diseases. These moves signal Lilly's ambition to diversify its portfolio and build a presence in cutting-edge therapeutic modalities. The expansion into ophthalmology and metabolic diseases through these partnerships was a notable development, highlighting the company's long-term growth strategy beyond its successful obesity and diabetes franchises.